(Celecoxib + tucidinostat) is under clinical development by Great Novel Therapeutics Biotech & Medicals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Celecoxib + tucidinostat)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Celecoxib + tucidinostat) overview
CC-01 a combination of celecoxib and tucidinostat is under development for the treatment of metastatic colorectal cancer. It is administered through oral route in the form of capsule and tablet. Celecoxib acts by targeting cyclooxygenase-2 and tucidinostat acts by targeting histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10.
Great Novel Therapeutics Biotech & Medicals overview
Great Novel Therapeutics Biotech & Medicals a subsidiary of Gold NanoTech Inc, is a manufacturer of nanoscale metallic particles for food and medical purposes. It is headquartered in Taipei City, Taipei, Taiwan.
For a complete picture of (Celecoxib + tucidinostat)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
